[HTML][HTML] Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy
A Porcari, G Sinagra, JD Gillmore, M Fontana… - European Journal of …, 2024 - Elsevier
Transthyretin amyloid cardiomyopathy (ATTR-CM) has been traditionally considered a rare
and inexorably fatal condition. ATTR-CM now is an increasingly recognized cause of heart …
and inexorably fatal condition. ATTR-CM now is an increasingly recognized cause of heart …
Current and evolving multimodality cardiac imaging in managing transthyretin amyloid cardiomyopathy
Amyloid transthyretin (ATTR) amyloidosis is a protein-misfolding disease characterized by
fibril accumulation in the extracellular space that can result in local tissue disruption and …
fibril accumulation in the extracellular space that can result in local tissue disruption and …
Clinical and prognostic implications of right ventricular uptake on bone scintigraphy in transthyretin amyloid cardiomyopathy
A Porcari, M Fontana, M Canepa, E Biagini, F Cappelli… - Circulation, 2024 - Am Heart Assoc
BACKGROUND: The extent of myocardial bone tracer uptake with technetium
pyrophosphate, hydroxymethylene diphosphonate, and 3, 3-diphosphono-1, 2 …
pyrophosphate, hydroxymethylene diphosphonate, and 3, 3-diphosphono-1, 2 …
SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy
Abstract Background Transthyretin cardiomyopathy (ATTR-CM) was an exclusion criterion in
randomized clinical trials of sodium-glucose cotransporter 2 inhibitors (SGLT2i). Objectives …
randomized clinical trials of sodium-glucose cotransporter 2 inhibitors (SGLT2i). Objectives …
[HTML][HTML] Safety review of therapeutic ultrasound for spinal cord neuromodulation and blood–spinal cord barrier opening
New focused ultrasound spinal cord applications have emerged, particularly those
improving therapeutic agent delivery to the spinal cord via blood–spinal cord barrier …
improving therapeutic agent delivery to the spinal cord via blood–spinal cord barrier …
Renal AL Amyloidosis: Updates on Diagnosis, Staging, and Management
AL amyloidosis is caused by the excessive production of nonfunctional immunoglobulins,
leading to the formation of amyloid fibrils that damage vital organs, especially the heart and …
leading to the formation of amyloid fibrils that damage vital organs, especially the heart and …
Histological Typing in Patients With Cardiac Amyloidosis: JACC Review Topic of the Week
E Gonzalez-Lopez, ED McPhail, C Salas-Anton… - Journal of the American …, 2024 - jacc.org
Cardiac amyloidosis is increasingly recognized as a treatable form of heart failure. Highly
effective specific therapies have recently become available for the 2 most frequent forms of …
effective specific therapies have recently become available for the 2 most frequent forms of …
Impact of the noninvasive diagnostic algorithm on clinical presentation and prognosis in cardiac amyloidosis
Background The introduction of a noninvasive diagnostic algorithm in 2016 led to increased
awareness and recognition of cardiac amyloidosis (CA). Objectives The purpose of this …
awareness and recognition of cardiac amyloidosis (CA). Objectives The purpose of this …
Diagnostic modalities and radiopharmaceuticals with particular importance of technetium-99m (99mTc)
N Ahmed, M Zia - Chinese Journal of Academic Radiology, 2023 - Springer
With the emergence of new diseases, a lot of advancements have been made in diagnosis
such as identification of new biomarkers, imaging techniques, radioisotopes tracking, and …
such as identification of new biomarkers, imaging techniques, radioisotopes tracking, and …
Quantitative SPECT/CT parameters in the assessment of transthyretin cardiac amyloidosis—a new dimension of molecular imaging
Aims: Cardiac transthyretin amyloidosis (ATTR) represents the accumulation of misfolded
transthyretin in the heart interstitium. Planar scintigraphy with bone-seeking tracers has long …
transthyretin in the heart interstitium. Planar scintigraphy with bone-seeking tracers has long …